Latest stories on CRMD
Cormedix gets FDA priority review for Rezzayo label expansion
Seeking Alpha64 · neutralproduct/pr
CorMedix Inc. (CRMD) files 8-K
SEC 8-K50 · neutralgeneral
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
Business Insider63 · neutralproduct/pr
Actinium Pharmaceuticals names former CorMedix executive as CFO
Seeking Alpha53 · neutralgeneral
Oppenheimer initiates CorMedix stock coverage with outperform rating
Investing.com Analyst Ratings61 · neutralanalyst
CorMedix initiated with an Outperform at Oppenheimer
The Fly63 · neutralanalyst
CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged
Yahoo Top63 · neutralearnings
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
Business Insider56 · neutralgeneral
CorMedix (CRMD) Q2 2026 Earnings Call Transcript
Yahoo Finance63 · neutralearnings
CorMedix (CRMD) Q2 2026 Earnings Call Transcript
The Motley Fool67 · bullishearnings
CorMedix: Durable Commercial Base, But 2027 Is The Real Test
Seeking Alpha58 · neutralgeneral
H.C. Wainwright reiterates CorMedix stock rating on strong quarter
Investing.com Analyst Ratings63 · neutralanalyst
CorMedix Inc. Q2 2026 Earnings Call Summary
Yahoo Top50 · neutralearnings
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
CorMedix shares jump 15% after Q2 earnings beat
Seeking Alpha68 · bullishearnings
Today's Stocks in the News
GlobeNewswire55 · neutralgeneral
CorMedix Q2 Earnings Call Highlights
Yahoo Top67 · bullishearnings
CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat
Stocktwits News63 · neutralproduct/pr
CorMedix Delivers Record Q2 Revenue and Raises 2026 EBITDA Outlook After DefenCath Expansion
August 13, 2026
MarketChameleon73 · bullishearnings
Why is CorMedix stock surging today?
Investing.com Markets50 · neutralgeneral
CorMedix Posts Robust Q2 Revenue, Ups EBITDA Guidance—DefenCath Drives Growth and Margin Expansion
August 13, 2026
MarketChameleon73 · bullishearnings
CorMedix rises after reporting Q3 results
Seeking Alpha67 · bullishearnings
CorMedix Inc. (CRMD) files 8-K
SEC 8-K50 · neutralgeneral
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire56 · neutralearnings